ClinicalTrials.gg

Program

KT-621

A development code.

Its studies are mostly in Dermatitis, Atopic · Asthma, led by Kymera Therapeutics.

Furthest: phase 2, since Oct 13, 20256 company-led studies, 4 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kymera Therapeutics64 open or runningphase 2since Oct 13, 2025Oct 23, 2024Apr 2027phase 1 · NCT07823205

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 23, 2024First study: phase 1 study in Healthy Participants StudyFirst studyNCT06673667 · 118 enrolled · United States
  2. Apr 9, 2025Phase 1 study in Dermatitis, AtopicNCT06945458 · 22 enrolled · United States
  3. Oct 13, 2025Phase 2 study in Dermatitis, AtopicNCT07217015 · 200 enrolled · United States, Australia, Canada and more
  4. Jan 6, 2026Phase 2 study in Pulmonary EosinophiliaNCT07323654 · 264 planned · United States, Argentina, Austria and more
  5. Jun 24, 2026Phase 2 study in AsthmaNCT07677059 · 264 planned · United States, Germany, Poland and more
  6. Sep 11, 2026Phase 1 study in Healthy ParticipantsNCT07823205 · 54 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07823205
  2. Jun 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07217015
  3. Dec 2027Primary completion: phase 2 study in Pulmonary EosinophiliaNCT07323654
  4. Dec 2028Primary completion: phase 2 study in AsthmaNCT07677059

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07823205Healthy Participants · United States1RecruitingApr 202754
NCT07677059Asthma · United States, Germany, Poland and more2RecruitingDec 2028264
NCT07323654Pulmonary Eosinophilia · United States, Argentina, Austria and more2RecruitingDec 2027264
NCT07217015Dermatitis, Atopic · United States, Australia, Canada and more2Active, not recruitingJun 2027200
NCT06945458Dermatitis, Atopic · United States1CompletedNov 10, 202522
NCT06673667Healthy Participants Study · United States1CompletedApr 23, 2025118

How it is read

Names in the registry

  • “KT-621”, 8 entries

Codes read as this program: KT621.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.